|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
2011-5-17
|
|
pubmed:abstractText |
At present there is no consensus on irradiation treatment volumes for intermediate to high-risk primary cancers or recurrent disease. Conventional imaging modalities, such as CT, MRI and transrectal ultrasound, are considered suboptimal for treatment decisions. Choline-PET/CT might be considered as the imaging modality in radiooncology to select and delineate clinical target volumes extending the prostate gland or prostate fossa. In conjunction with intensity modulated radiotherapy (IMRT) and imaged guided radiotherapy (IGRT), it might offer the opportunity of dose escalation to selected sites while avoiding unnecessary irradiation of healthy tissues.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-11196147,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-12620996,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-12814672,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-16044216,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-16099293,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-16452561,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-16865395,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-17428249,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-17538167,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-18410442,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-19234708,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-20298546,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-20708811,
http://linkedlifedata.com/resource/pubmed/commentcorrection/21529377-9627331
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1748-717X
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
44
|
|
pubmed:meshHeading |
pubmed-meshheading:21529377-Aged,
pubmed-meshheading:21529377-Carcinoma,
pubmed-meshheading:21529377-Choline,
pubmed-meshheading:21529377-Humans,
pubmed-meshheading:21529377-Lymph Nodes,
pubmed-meshheading:21529377-Lymphatic Metastasis,
pubmed-meshheading:21529377-Male,
pubmed-meshheading:21529377-Middle Aged,
pubmed-meshheading:21529377-Neoplasm Staging,
pubmed-meshheading:21529377-Positron-Emission Tomography,
pubmed-meshheading:21529377-Prostatic Neoplasms,
pubmed-meshheading:21529377-Radiotherapy, Intensity-Modulated,
pubmed-meshheading:21529377-Radiotherapy Dosage,
pubmed-meshheading:21529377-Radiotherapy Planning, Computer-Assisted,
pubmed-meshheading:21529377-Recurrence,
pubmed-meshheading:21529377-Tomography, X-Ray Computed
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
[18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes.
|
|
pubmed:affiliation |
Radiologische Allianz Hamburg, D-22767 Hamburg, Germany. florian.wuerschmidt@radiologische-allianz.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
